InhyeAhnMD

PubMed

• Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL.
  Ahn, I., Brander, D., Ren, Y., Zhou, Y., Tyekucheva, S., Walker, H., Black, R., Montegaard, J., Alencar, A., Shune, L., Omaira, M., Jacobson, C., Armand, P., Ng, S., C...> ;Blood Advances. 2024 Feb 27
• Therapeutic targeting of apoptosis in chronic lymphocytic leukemia.
  Inhye E Ahn, Matthew S Davids> ;Seminars in Hematology. 2024 Feb 7
• 2 citations
  Prognostic Markers in the Era of Targeted Therapies.
  Sorang Kang, Ahn, I.> ;Acta Haematologica. 2024 Jan 1
• A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphoma.
  Reid W Merryman, Robert A Redd, Arnold S Freedman, Inhye E Ahn, Jennifer R Brown, Jennifer L Crombie, Matthew S Davids, David C Fisher, Eric D Jacobsen, Austin I Kim, ...> ;Annals of Hematology. 2024 Jan 1
• CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy.
  Alsadhan, A., Chen, J., Gaglione, E., Underbayev, C., Tuma, P., Tian, X., Freeman, L., Baskar, S., Nierman, P., Soto, S., Itsara, A., Ahn, I., Sun, C., Bibikova, E., H...> ;Clinical Cancer Research. 2023 Sep 15
• 2 citations
  B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy.
  Jennifer A Woyach, Paolo Ghia, John C Byrd, Inhye E Ahn, Carol Moreno, Susan M O'Brien, Daniel Jones, Leo W K Cheung, Elizabeth Chong, Kevin Kwei, James P Dean, Danell...> ;Clinical Cancer Research. 2023 Aug 15
• CD49d expression identifies a biologically distinct subtype of chronic lymphocytic leukemia with inferior progression-free survival on BTK inhibitor therapy.
  Anfal Alsadhan, Jonathan Chen, Erika M Gaglione, Chingiz Underbayev, Pamela L Tuma, Xin Tian, Lita A Freeman, Sivasubramanian Baskar, Pia Nierman, Susan Soto, Andy Its...> ;Clinical Cancer Research. 2023 May 9
• Interim Positron Emission Tomography During Frontline Chemoimmunotherapy for Follicular Lymphoma.
  Merryman, R., Michaud, L., Redd, R., Mondello, P., Park, H., Spilberg, G., Robertson, M., Taranto, E., Ahmed, G., Chase, M., Jeter, E., Ahn, I., Brown, J., Crombie, J....> ;Hemasphere. 2023 Feb 1
• 1 citations
  Characteristics and Clinical Outcomes of Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Receiving Ibrutinib for ≥5 Years in the RESONATE-2 Study.
  Jennifer A Woyach, Paul M Barr, Thomas J Kipps, Jacqueline C Barrientos, Inhye E Ahn, Paolo Ghia, Vincent Girardi, Emily Hsu, Mandy Jermain, Jan A Burger> ;Cancers. 2023 Jan 13
• 4 citations
  Selecting initial therapy in CLL.
  Inhye E Ahn, Jennifer R Brown> ;Hematology. American Society of Hematology. Education Program. 2022 Dec 9
• 8 citations
  NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient-derived xenografts.
  Deyi Zhang, Hailey M Harris, Jonathan Chen, Jen Judy, Gabriella James, Aileen Kelly, Joel McIntosh, Austin Tenn-McClellan, Eileen Ambing, Ying Siow Tan, Hao Lu, Stefan...> ;Blood. 2023 Mar 30
• 13 citations
  BTK inhibitors impair humoral and cellular responses to recombinant zoster vaccine in CLL.
  Christopher Pleyer, Kerry J Laing, Mir A Ali, Christopher L McClurkan, Susan Soto, Inhye E Ahn, Pia Nierman, Emeline Maddux, Jennifer Lotter, Jeanine Superata, Xin Tia...> ;Blood Advances. 2022 Mar 22
• 46 citations
  COVID-19 in patients with CLL: improved survival outcomes and update on management strategies.
  Lindsey E. Roeker, Toby A. Eyre, Meghan C. Thompson, Nicole Lamanna, Alexander Coltoff, Matthew S. Davids, PK Baker, Lori A. Leslie, Kerry A. Rogers, John N. Allan, Ra...> ;Blood. 2021 Jul 23
• 12 citations
  BTK Inhibitors, Irrespective of ITK Inhibition, Increase Efficacy of a CD19/CD3 Bispecific Antibody in CLL.
  Maissa Mhibik, Erika M Gaglione, David Eik, Ellen K Kendall, Amy Blackburn, Keyvan Keyvanfar, Maria Joao Baptista, Inhye E. Ahn, Clare Sun, Junpeng Qi, Christoph Rader...> ;Blood. 2021 Nov 11
• 94 citations
  Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines.
  Christopher Pleyer, Mir A. Ali, Jeffrey I. Cohen, Xin Tian, Susan Soto, Inhye E. Ahn, Erika M Gaglione, Pia Nierman, Gerald E. Marti, Charles S. Hesdorffer, Jennifer L...> ;Blood. 2021 Jan 14
• 68 citations
  Ibrutinib for Chronic Lymphocytic Leukemia with TP53 Alterations
  Inhye E. Ahn, Xin Tian> ;The New England Journal of Medicine. 2020 Jul 29
• 12 citations
  Cardiovascular adverse events of ibrutinib.
  Inhye E. Ahn> ;Blood. 2019 Nov 28
• 1 citations
  Safety profiles of novel agent therapies in CLL.
  Inhye E. Ahn, Matthew S. Davids> ;Hematology. American Society of Hematology. Education Program. 2017 Dec 8
• 19 citations
  Draft genome of the Antarctic dragonfish, Parachaenichthys charcoti
  Do-Hwan Ahn, Seung Chul Shin, Bo-Mi Kim, Seunghyun Kang, Jin-Hyoung Kim, Inhye Ahn, Joonho Park, Hyun Park> ;Gigascience. 2017 Aug 1
• 20 citations
  Using high-sensitivity sequencing for the detection of mutations in BTK and PLCγ2 genes in cellular and cell-free DNA and correlation with progression in patients trea...
  Adam Albitar, Wanlong Ma, Ivan DeDios, Jeffrey Estella, Inhye E. Ahn, Mohammed Farooqui, Maher Albitar> ;Oncotarget. 2017 Feb 14
• 10 citations
  Successful Long-Term Treatment of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms With Combination of Hydroxyurea and Anagrelide
  Inhye E. Ahn, Ethan A. Natelson, Lawrence Rice> ;Clinical Lymphoma, Myeloma & Leukemia. 2013 Sep 1
• 17 citations
  Cost analysis of asymmetric sensorineural hearing loss investigations.
  Yu Shan L. Wilson, Michele M. Gandolfi, Inhye E. Ahn, Guopei Yu, Tina C. Huang, Ana H. Kim> ;The Laryngoscope. 2009 Jan 1
• 25 citations
  Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials.
  John N Allan, Tait Shanafelt, Carol Moreno, Susan M O'Brien, Jianling Li, Gabriel Krigsfeld, James P Dean, Inhye E Ahn, Adrian Wiestner> ;British Journal of Haematology. 2022 Feb 1
• 22 citations
  Overcoming Acquired Epigenetic Resistance to BTK Inhibitors
  , , , , , , , , , , , , , , , , , , , , , , , , , , , , , > ;Blood Cancer Discovery. 2021 Sep 14
• 39 citations
  Targeting Bruton's Tyrosine Kinase in CLL.
  Inhye E. Ahn, Jennifer R. Brown> ;Frontiers in Immunology. 2021 Jun 23
• Join now to see all

Abstracts/Posters

• A CD19/CD3 Bispecific Antibody Induces Superior T Cell Responses Against Chronic Lymphocytic Leukemia When Combined with Ibrutinib
  Inhye E Ahn, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Response to the Shingrix Varicella Zoster Virus (VZV) Vaccine in Patients with Chronic Lymphocytic Leukemia (CLL) That Are Treatment Naive or Treated with a Bruton's T...
  Inhye E Ahn, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib Show Expansion of T-Cell Clonotypes Composed of Antitumor Cytotoxic CD8+ T-Cells
  Inhye E Ahn, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Whole Exome Sequencing Reveals Multiple Driver Events in Chronic Lymphocytic Leukemia Patients with Acquired Ibrutinib Resistance
  Inhye E Ahn, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Join now to see all